Growth signaling in breast cancer cells: Outcomes and promises of proteomics

Biochemical Pharmacology

Volumn 64, Issue 5-6, 2002, Pages 797-803

  Adriaenssens, Eric ^a   Lemoine, Jérôme ^b   El Yazidi Belkoura, Ikram ^a   Hondermarck, Hubert ^a  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

Breast cancer; Growth factors; Oncogenes; Proteomics; Signaling pathways

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELLULAR PARAMETERS; CONTROLLED STUDY; GENE TARGETING; GENOMICS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 0036711321     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01141-3     Document Type: Article

References (44)

1. Pandey A., Mann M. Proteomics to study genes and genomes. Nature. 405:2000;837-846.
2. Banks R.E., Dunn M.J., Hochstrasser D.F., Sanchez J.C., Blackstock W., Pappin D.J., Selby P.J. Proteomics: new perspectives, new biomedical opportunities. Lancet. 356:2000;1749-1756.
3. Hondermarck H., Vercoutter-Edouart A.S., Revillion F., Lemoine J., El-Yazidi-Belkoura I., Nurcombe V., Peyrat J.P. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 1:2001;1216-1232.
4. Miklos G.L., Maleszka R. Protein functions and biological contexts. Proteomics. 1:2001;169-178.
5. Godovac-Zimmermann J., Soskic V., Poznanovic S., Brianza F. Functional proteomics of signal transduction by membrane receptors. Electrophoresis. 20:1999;952-961.
6. Steen H., Kuster B., Fernandez M., Pandey A., Mann M. Tyrosine phosphorylation mapping of the epidermal growth factor receptor signaling pathway. J. Biol. Chem. 277:2002;1031-1039.
7. Hondermarck H., McLaughlin C.S., Patterson S.D., Bradshaw R.A. Early changes in protein synthesis induced by basic fibroblast growth factor, nerve growth factor, and epidermal growth factor in PC12 pheochromocytoma cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9377-9381.
8. Soskic V., Gorlach M., Poznanovic S., Boehmer F.D., Godovac-Zimmermann J. Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. Biochemistry. 38:1999;1757-1764.
9. Pandey A., Podtelejnikov A.V., Blagoev B., Bustelo X.R., Mann M., Lodish H.F. Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 97:2000;179-184.
10. Haber D. Roads leading to breast cancer. N. Engl. J. Med. 343:2000;1566-1568.
11. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339:1998;1609-1618.
12. Ethier S.P. Growth factor synthesis and human breast cancer progression. J. Natl. Cancer Inst. 87:1995;964-973.
13. Le Bourhis X., Toillon R.A., Boilly B., Hondermarck H. Autocrine and paracrine growth inhibition of breast cancer cells. Breast Cancer Res. Treat. 1722:2000;1-8.
14. Rahimi N., Hung W., Tremblay E., Saulnier R., Elliott B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273:1998;33714-33721.
15. Nurcombe V., Smart C.E., Chipperfield H., Cool S.M., Boilly B., Hondermarck H. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J. Biol. Chem. 275:2000;30009-30018.
16. Descamps S., Lebourhis X., Delehedde M., Boilly B., Hondermarck H. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J. Biol. Chem. 273:1998;16659-16662.
17. Descamps S., Toillon R.A., Adriaenssens E., Pawlowski V., Cool S.M., Nurcombe V., Le Bourhis X., Boilly B., Peyrat J.P., Hondermarck H. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J. Biol. Chem. 276:2001;17864-17870.
18. Ornitz D.M., Nobuyuki I. Fibroblast growth factors. Genome Biol. 2:2001;3005.1-3005.12.
19. Blanckaert V.D., Hebbar M., Louchez M.M., Vilain M.O., Schelling M.E., Peyrat J.P. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin. Cancer Res. 4:1998;2939-2947.
20. Rahmoune H., Chen H.L., Gallagher J.T., Rudland P.S., Fernig D.G. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J. Biol. Chem. 273:1998;7303-7310.
21. Boilly B., Vercoutter-Edouart A.S., Hondermarck H., Nurcombe V., Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 11:2000;295-302.
22. Liu J.F., Chevet E., Kebache S., Lemaitre G., Barritault D., Larose L., Crepin M. Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells. Oncogene. 18:1999;6425-6433.
23. Vercoutter-Edouart A.S., Lemoine J., Smart C.E., Nurcombe V., Boilly B., Peyrat J.P., Hondermarck H. The mitogenic signaling pathway for fibroblast growth factor-2 involves the tyrosine phosphorylation of cyclin D2 in MCF-7 human breast cancer cells. FEBS Lett. 478:2000;209-215.
24. Vercoutter-Edouart A.S., Czeszak X., Crepin M., Lemoine J., Boilly B., Le Bourhis X., Peyrat J.P., Hondermarck H. Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2 in MCF-7 human breast cancer cells. Exp. Cell Res. 262:2001;59-68.
25. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 92:2000;1564-1572.
26. Pearl L.H., Prodromou C. Structure and in vivo function of Hsp90. Curr. Opin. Struct. Biol. 10:2000;46-51.
27. Brannan C.I., Dees E.C., Ingram R.S., Tilghman S.M. The product of the H19 gene may function as an RNA. Mol. Cell Biol. 10:1990;28-36.
28. Hao Y., Crenshaw T., Moulton T., Newcomb E., Tycko B. Tumour-suppressor activity of H19 RNA. Nature. 365:1993;764-767.
29. Lottin S, Vercoutter-Edouart AS, Adriaenssens E, Czezak X, Lemoine J, Roudbaraki M, Coll J, Hondermarck H, Dugimont T, Curgy JJ. Thioredoxin post-transcriptional regulation by H19 provides a new function to non-coding mRNA. Oncogene 2002;21:1625-31.
30. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Annu. Rev. Immunol. 15:1997;351-369.
31. Hirota K., Murata M., Itoh T., Yodoi J., Fukuda K. Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J. Biol. Chem. 276(28):2001, July;25953-25958.
32. Adriaenssens E, Lottin S, Berteaux N, Hornez L, Fauquette W, Fafeur V, Peyrat JP, LeBourhis X, Hondermarck H, Coll J, Dugimont T, Curgy JJ. Cross-talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp Cell Res, in press.
33. Fu H., Subramanian R.R., Masters S.C. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40:2000;617-647.
34. Ferguson A.T., Evron E., Umbricht C.B., Pandita T.K., Chan T.A., Hermeking H., Marks J.R., Lambers A.R., Futreal P.A., Stampfer M.R., Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6049-6054.
35. Vercoutter-Edouart A.S., Lemoine J., Le Bourhis X., Louis H., Boilly B., Nurcombe V., Revillion F., Peyrat J.P., Hondermarck H. Proteomic analysis reveals that 14-3-3 sigma is down-regulated in human breast cancer cells. Cancer Res. 61:2001;76-80.
36. Li S., Shipley G.D. Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Diff. 2:1991;195-202.
37. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:1997;3-11.
38. Laronga C., Yang H.Y., Neal C., Lee M.H. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J. Biol. Chem. 275:2000;23106-23112.
39. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics. 2(1):2002, January;3-10.
40. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:1999;994-999.
41. Fung E.T., Thulasiraman V., Weinberger S.R., Dalmasso E.A. Protein biochips for differential profiling. Curr. Opin. Biotechnol. 12:2001;65-69.
42. Gygi S.P., Aebersold R. Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 4:2000;489-494.
43. Goshe M.B., Conrads T.P., Panisko E.A., Angell N.H., Veenstra T.D., Smith R.D. Phosphoprotein Isotope-Coded Affinity Tag approach for isolating and quantitating phosphopeptides in proteome-wide analyses. Anal. Chem. 73:2001;2578-2586.
44. Chalmers M.J., Gaskell S.J. Advances in mass spectrometry for proteome analysis. Curr. Opin. Biotechnol. 11:2000;384-390.